Intranasal Esketamine + CBT: a 6 months follow-up of a resistant depression complicated case

INTRODUCTION: TRD is a highly disabling condition, often responsible for chronic clinical course, high number of relapses and elevated suicide risk. Intranasal esketamine is currently the only available pharmacological therapy specifically indicated for TRD, as add-on therapy to antidepressant treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Martiadis, V., Raffone, F., Cerlino, R., Mistico, F., Russo, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9567915/
http://dx.doi.org/10.1192/j.eurpsy.2022.1431

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9567915/
http://dx.doi.org/10.1192/j.eurpsy.2022.1431

Ejemplares similares